Abstract
Recently, BRC has been proposed as a novel agent for the treatment of tall stature in adolescents based on its ability to reduce adult height prediction (HP). Eight boys with a chronological age of 10.3-15.4 yrs (mean 13.3 yrs) were treated for 1 yr with BRC 7.5 mg daily. At the onset of therapy, adult height prediction according to Bayley-Pinneau (HP-BP) was 200.7 to 209.7 cm and according to Tanner Mark II (HP-TWII) 199.0-211.5 cm. After 1 yr of therapy, HP with both methods had decreased in every boy, changing by -4.13±1.86(SD) cm (HP-BP) or -3.35±2.39(SD) cm (HP-TWII), respectively. To substantiate these findings, each patient was pair-matched with a control, an untreated boy with a height above +2SDS and a bone age differing less than 0.5 yr. HP-BP was significantly reduced in patients after 1 yr of BRC compared with their matched controls after 1 yr of follow-up (p less than 0.02). By contrast, differences in HP-TWII were not significant. Because of this discrepancy it is uncertain whether final height in tall boys will really be reduced by treatment with BRC.
BRC was kindly provided by Dr. R. Schmidt, Sandoz Ltd.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwarz, H., Joss, E. & Zuppinger, K. BROMOCRIPTINE (BRC) TREATMENT IN EXCESSIVELY TALL BOYS. A PAIR-MATCHED CONTROLLED STUDY. Pediatr Res 20, 1196 (1986). https://doi.org/10.1203/00006450-198611000-00138
Issue date:
DOI: https://doi.org/10.1203/00006450-198611000-00138
